The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
227
Specified dose on specified days
Specified dose on specified days
Incidence of treatment emergent adverse events (TEAEs)
Time frame: Up to approximately 24 weeks
Incidence of serious adverse events (SAEs)
Time frame: Up to approximately 24 weeks
Incidence of AEs leading to treatment discontinuation
Time frame: Up to approximately 20 weeks
Summary of plasma concentrations of MYK-224
Time frame: Up to approximately 20 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Local Institution - 0002
Birmingham, Alabama, United States
Local Institution - 0096
Lakewood, Colorado, United States
Local Institution - 0077
Jacksonville, Florida, United States
Local Institution - 0003
Miami, Florida, United States
Local Institution - 0099
Miami, Florida, United States
Local Institution - 0004
Chicago, Illinois, United States
Local Institution - 0005
Hazel Crest, Illinois, United States
Local Institution - 0029
Indianapolis, Indiana, United States
Local Institution - 0028
St Louis, Missouri, United States
Local Institution - 0117
Hackensack, New Jersey, United States
...and 76 more locations